Combining Proprietary Bacteriophage Technology and Pet Food Development Expertise

AI pet healthcare startup Limpid has announced that it will jointly develop a pet healthcare solution utilizing bacteriophages in partnership with Qurencis Bio.


Limpid Signs Joint Development Agreement for Pet Healthcare Solutions with Qurencis Bio View original image

On July 20, Limpid stated that it has signed a joint research and development agreement for pet gut health and immune functionality products with Qurencis Bio at the Limpid Research Center in Yongsan-gu, Seoul.


Qurencis Bio is a bio-technology company that originated as an in-house venture of CJ CheilJedang and later spun off, possessing proprietary technology for developing eco-friendly antibacterial microorganisms called bacteriophages, which selectively eliminate only harmful bacteria.


The two companies have agreed to jointly develop products by combining Qurencis Bio’s bacteriophage materials with Limpid’s expertise in veterinary nutrition and pet food development.


Since the time when Qurencis Bio was still an in-house venture of CJ CheilJedang, researchers from both companies have been engaged in collaborative studies. Limpid is currently verifying, through its pet food and supplements clinical trial institution, the LVRC (LV Veterinary Research Center), the ability of bacteriophages to destroy the causative bacteria of canine otitis externa (bacteriolytic activity).


The companies plan to expand the antibacterial efficacy of bacteriophages as functional materials for pet food and supplements.


Heesoo Kim, CEO of Limpid, stated, "Our goal is to translate the efficacy of bacteriophages—proven in conditions with high recurrence rates and antibiotic resistance, such as otitis externa—into pet food and supplements, and to introduce functional pet food that does not rely on antibiotics."


Jongsoo Jeon, CEO of Qurencis Bio, commented, "Limpid is the optimal partner to bring the value of bacteriophages into real products in the pet industry, and we will accelerate commercialization based on our joint research achievements."



Founded in 2020, Limpid is an AI pet healthcare startup offering various businesses such as SaladPet, TrustyFood, DrTrusty, and Kinfora. The company operates the LVRC, a clinical trial institution specializing in pet food and supplement materials, in collaboration with Kyungpook National University Technology Holdings.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing